Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
4 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Recursion Pharmaceuticals (NASDAQ: RXRX ) reported second-quarter financial results on Wednesday. The transcript from the company's second-quarter earnings call has been provided below. This content is powered APIs. For comprehensive financial data and transcripts, visit Access the full call at Summary Recursion Pharma
Novartis (NYSE: NVS ) reported second-quarter financial results on Tuesday. The transcript from the company's second-quarter earnings call has been provided below. APIs provide real-time access to earnings call transcripts and financial data. Visit to learn more. View the webcast at Watch the full earnings call below
NVS Novartis RESULTS: Q2, Q2 net sales $14.408B vs. EST $14.042B, Q2 core EPS $2.41 vs. EST $2.13, Q2 Net Income $3.257B, Q2 core Net Income $4.578B, Q2 core Operating Income $5.940B, Q2 EPS $1.71, Novartis Earnings Notes:, Full-year 2026 guidance2 reaffirmed, Net debt increased to $39.4B at June 30, 2026, compared to
Net Sales $14.41B (est $13.94B) - Core EPS $2.41 (est $2.16) - Promacta/Revolade Sales $179M (est $202.1M) - Tasigna Sales $142M (est $147.2M) - Kisqali Sales $1.70B (est $1.68B) - Pluvicto Sales $651M (est $671.7M) - Entresto Sales $1.18B (est $1.29B) - Cosentyx Sales $1.82B (est $1.14B) - FY 2026 Guidance Reaffirmed